Skip to main content
Top
Published in: Cardiovascular Drugs and Therapy 2/2018

Open Access 01-04-2018 | SHORT COMMUNICATION

Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute

Authors: Xavier Rossello, Zhenhe He, Derek M. Yellon

Published in: Cardiovascular Drugs and Therapy | Issue 2/2018

Login to get access

Abstract

Purpose

To accurately estimate the effect size of both local or classic ischaemic preconditioning (IPC) and remote ischaemic preconditioning (RIPC) using a pooling data set of 91 animals.

Methods

We combined all the available mouse data collected from our Institute over the last 3 years regarding (i) local IPC (4 cycles of 5 min of global ischaemia/reperfusion injury, IRI, followed by 35-min ischaemia and 2-h reperfusion) in the Langendorff-isolated perfused mouse heart model and (ii) RIPC (3 cycles of 5 min of limb occlusion followed by 40-min ischaemia and 2-h reperfusion) in the in vivo mouse model.

Results

Five independent experiments containing 27 control and 29 IPC mice were used to estimate the overall (i) local IPC effect, which reduced infarct size in the ex-vivo setting by a mean difference of 24.1% (95% CI 19.5, 28.6%) when compared to untreated controls (P < 0.001) and for (ii) RIPC, three independent experiments including data for 16 control and 19 RIPC mice were used to estimate that RIPC diminished infarct size in the in-vivo setting by a mean difference of 20.8% (95% CI 14.7, 26.9%) when compared to controls (P < 0.001).

Conclusions

Using a significant animal dataset, we found that local IPC reduces myocardial infarct size by 24.1% and RIPC by 20.8% in the ex vivo and in vivo mouse models of IRI, respectively. These differences may be used as reference values to either establish positive controls or to determine by how much myocardial infarct size can be reduced by novel cardioprotective interventions following an IRI insult.
Literature
1.
go back to reference Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I. Reviewing animal trials systematically (RATS) group. Where is the evidence that animal research benefits humans? BMJ. 2004;328:514–7.CrossRefPubMedPubMedCentral Pound P, Ebrahim S, Sandercock P, Bracken MB, Roberts I. Reviewing animal trials systematically (RATS) group. Where is the evidence that animal research benefits humans? BMJ. 2004;328:514–7.CrossRefPubMedPubMedCentral
2.
go back to reference Fuster V. Top 10 cardiovascular therapies and interventions for the next decade. Nat Rev Cardiol. 2014;11:671–83.CrossRefPubMed Fuster V. Top 10 cardiovascular therapies and interventions for the next decade. Nat Rev Cardiol. 2014;11:671–83.CrossRefPubMed
3.
go back to reference Rossello X, Yellon DM. A critical review on the translational journey of cardioprotective therapies! Int J Cardiol. Elsevier; 2016;220:176–84. Rossello X, Yellon DM. A critical review on the translational journey of cardioprotective therapies! Int J Cardiol. Elsevier; 2016;220:176–84.
4.
go back to reference Bromage DI, Pickard JMJ, Rossello X, Ziff OJ, Burke N, Yellon DM, et al. Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res. 2016;113:288–97.PubMedCentral Bromage DI, Pickard JMJ, Rossello X, Ziff OJ, Burke N, Yellon DM, et al. Remote ischaemic conditioning reduces infarct size in animal in vivo models of ischaemia-reperfusion injury: a systematic review and meta-analysis. Cardiovasc Res. 2016;113:288–97.PubMedCentral
5.
go back to reference Johnsen J, Pryds K, Salman R, Løfgren B, Kristiansen SB, Bøtker HE. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol. 2016;111:10.CrossRefPubMed Johnsen J, Pryds K, Salman R, Løfgren B, Kristiansen SB, Bøtker HE. The remote ischemic preconditioning algorithm: effect of number of cycles, cycle duration and effector organ mass on efficacy of protection. Basic Res Cardiol. 2016;111:10.CrossRefPubMed
6.
go back to reference Wever KE, Hooijmans CR, Riksen NP, Sterenborg TB, Sena ES, Ritskes-Hoitinga M, et al. Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies. PLoS One. 2015;10:e0142021.CrossRefPubMedPubMedCentral Wever KE, Hooijmans CR, Riksen NP, Sterenborg TB, Sena ES, Ritskes-Hoitinga M, et al. Determinants of the efficacy of cardiac ischemic preconditioning: a systematic review and meta-analysis of animal studies. PLoS One. 2015;10:e0142021.CrossRefPubMedPubMedCentral
7.
go back to reference Rossello X, Burke N, Stoppe C, Bernhagen J, Davidson SM, Yellon DM. Exogenous administration of recombinant MIF at physiological concentrations failed to attenuate infarct size in a Langendorff perfused isolated mouse heart model. Cardiovasc Drugs Ther. 2016;30:445–53.CrossRefPubMedPubMedCentral Rossello X, Burke N, Stoppe C, Bernhagen J, Davidson SM, Yellon DM. Exogenous administration of recombinant MIF at physiological concentrations failed to attenuate infarct size in a Langendorff perfused isolated mouse heart model. Cardiovasc Drugs Ther. 2016;30:445–53.CrossRefPubMedPubMedCentral
8.
go back to reference Rossello X, Riquelme JA, Davidson SM, Yellon DM. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J Cell Mol Med. 2017;22:926–35.PubMedPubMedCentral Rossello X, Riquelme JA, Davidson SM, Yellon DM. Role of PI3K in myocardial ischaemic preconditioning: mapping pro-survival cascades at the trigger phase and at reperfusion. J Cell Mol Med. 2017;22:926–35.PubMedPubMedCentral
9.
go back to reference Rossello X, Riquelme JA, He Z, Taferner S, Vanhaesebroeck B, Davidson SM, et al. The role of PI3Kα isoform in cardioprotection. Basic Res Cardiol. 2017;112:66.CrossRefPubMedPubMedCentral Rossello X, Riquelme JA, He Z, Taferner S, Vanhaesebroeck B, Davidson SM, et al. The role of PI3Kα isoform in cardioprotection. Basic Res Cardiol. 2017;112:66.CrossRefPubMedPubMedCentral
10.
go back to reference Rossello X, Hall AR, Bell RM, Yellon DM. Characterization of the Langendorff perfused isolated mouse heart model of global ischemia-reperfusion injury: impact of ischemia and reperfusion length on infarct size and LDH release. J Cardiovasc Pharmacol Ther. 2015;21:286–95.CrossRefPubMed Rossello X, Hall AR, Bell RM, Yellon DM. Characterization of the Langendorff perfused isolated mouse heart model of global ischemia-reperfusion injury: impact of ischemia and reperfusion length on infarct size and LDH release. J Cardiovasc Pharmacol Ther. 2015;21:286–95.CrossRefPubMed
11.
go back to reference Klein HH, Puschmann S, Schaper J, Schaper W. Vircho Archiv A the mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virchows Arch [Pathol Anat]. 1981;393:287–97.CrossRef Klein HH, Puschmann S, Schaper J, Schaper W. Vircho Archiv A the mechanism of the tetrazolium reaction in identifying experimental myocardial infarction. Virchows Arch [Pathol Anat]. 1981;393:287–97.CrossRef
12.
go back to reference Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.CrossRefPubMedPubMedCentral Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG. Improving bioscience research reporting: the ARRIVE guidelines for reporting animal research. PLoS Biol. 2010;8:e1000412.CrossRefPubMedPubMedCentral
14.
go back to reference Wever KE, Menting TP, Rovers M, van der Vliet JA, Rongen GA, Masereeuw R, Ritskes-Hoitinga M, Hooijmans CR, Warlé M. Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. Eltzschig HK, editor. PLoS One 2012;7:e32296. Wever KE, Menting TP, Rovers M, van der Vliet JA, Rongen GA, Masereeuw R, Ritskes-Hoitinga M, Hooijmans CR, Warlé M. Ischemic preconditioning in the animal kidney, a systematic review and meta-analysis. Eltzschig HK, editor. PLoS One 2012;7:e32296.
15.
go back to reference Rossello X, Yellon DM. Cardioprotection: the disconnect between bench and bedside. Circulation. 2016;134:574–5.CrossRefPubMed Rossello X, Yellon DM. Cardioprotection: the disconnect between bench and bedside. Circulation. 2016;134:574–5.CrossRefPubMed
Metadata
Title
Myocardial Infarct Size Reduction Provided by Local and Remote Ischaemic Preconditioning: References Values from the Hatter Cardiovascular Institute
Authors
Xavier Rossello
Zhenhe He
Derek M. Yellon
Publication date
01-04-2018
Publisher
Springer US
Published in
Cardiovascular Drugs and Therapy / Issue 2/2018
Print ISSN: 0920-3206
Electronic ISSN: 1573-7241
DOI
https://doi.org/10.1007/s10557-018-6788-8

Other articles of this Issue 2/2018

Cardiovascular Drugs and Therapy 2/2018 Go to the issue